National CMOP FENOFIBRATE

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 15 is conducting a sources sought market research for FENOFIBRATE pharmaceutical products, specifically 48MG and 145MG tablets in 90-count bottles. This pre-solicitation notice (Solicitation Number 36C77025Q0248) seeks potential vendors who can manufacture or supply these pharmaceutical products with compliance to USA/BAA/TAA standards. Interested vendors must submit a capability statement by June 4, 2025, at 4:00 PM Central Time via email to Jennifer.Knight@va.gov, and must provide their SAM Unique ID Number and detailed company contact information. The VA is specifically requesting comprehensive information about manufacturing locations, pharmaceutical state wholesale licenses, and the vendor's business size classification (Small Disadvantaged Business, Veteran-Owned Small Business, or Large Business). Evaluation criteria will focus on vendor capabilities, compliance with regulatory requirements, and ability to meet the VA Consolidated Mail Outpatient Pharmacy (CMOP) system's strict pharmaceutical procurement standards.

The sources sought notice does not indicate a specific set-aside designation, meaning businesses of all sizes can potentially compete for this opportunity. While no specific award value or budget range is mentioned, the procurement is targeted at the Pharmaceutical Preparation Manufacturing (NAICS 325412) sector with a Product Service Code of 6505 for Drugs and Biologicals. The VA requires vendors to demonstrate full compliance with the Drug Supply Chain Security Act, provide comprehensive transaction documentation, and meet detailed specifications including bar coding standards, lot number tracking, and FDA regulatory adherence. Vendors must be prepared to provide extensive product information, including NDC numbers, container sizes, and ownership transfer details. The document emphasizes that this is a market research effort only, and no immediate quotes are being solicited, suggesting a potential future competitive procurement process for these pharmaceutical products.